Abstract
The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates. This article describes increasing levels of restrictions for use in pharmacoepidemiology and examines to what extent they change rate ratio estimates and reduce bias in a study of statin treatment and 1-year mortality. : The study cohort was drawn from a population of seniors age 65 years and older enrolled in both Medicare and the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) between 1995 and 2002. We identified all users of statins during the study period and assessed the time until death within 1 year. The following progressive restrictions were applied: (1) study incident drug users only, (2) choose a comparison group most similar to the intervention group, (3) exclude patients with contraindications, (4) exclude patients with low adherence, and (5) restrict to specific high-risk/low-risk subgroups represented in randomized trails (RCTs). The basic cohort comprised 122,406 statin users, who were on average 78 years old and predominantly white (93%) and showed an unadjusted rate ratio of 0.32 for statin users. When all 5 restrictions were applied (N = 11,673), the unadjusted rate ratio had increased to 0.72. Multivariable Cox regression adjusted rate ratios increased from 0.62 [95% confidence interval (CI), 0.58-0.66] to 0.79 (95% CI, 0.60-1.03). However, after the first 3 restrictions the effect size changed little. The final estimate is similar to that obtained as a pooled estimate of 3 pravastatin RCTs in patients age 65 years and older. We argue that restrictions 1 through 4 compromised generalizability little. In our example of a large database study, restricting to incident drug users, similar comparison groups, patients without contraindication, and to adherent patients was a practical strategy, which limited the effect of confounding, as these approaches yield results closer to those seen in RCTs.
MeSH Terms
Aged
Aged, 80 and over
Confounding Factors, Epidemiologic
Control Groups
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Male
Matched-Pair Analysis
Mortality
Multivariate Analysis
Patient Compliance
Patient Selection
Pennsylvania/epidemiology
Pharmacoepidemiology/statistics & numerical data
Proportional Hazards Models
Randomized Controlled Trials as Topic
Reproducibility of Results
Research Design
Retrospective Studies
Risk Adjustment
United States/epidemiology
Chemicals
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schneeweiss Sebastian
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
[email protected]
Patrick Amanda R
Stürmer Til
Brookhart M Alan
Avorn Jerry
Maclure Malcolm
Rothman Kenneth J
Glynn Robert J
References (23)
23 references, click to expand
-
Channeling bias in the interpretation of drug effects.
Stat Med. 1991 Apr;10(4):577-81
PMID: 2057656
-
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.
Lancet. 2005 Jan 8-14;365(9454):176-86
PMID: 15639301
-
Why we need observational studies to evaluate the effectiveness of health care.
BMJ. 1996 May 11;312(7040):1215-8
PMID: 8634569
-
Causation of bias: the episcope.
Epidemiology. 2001 Jan;12(1):114-22
PMID: 11138805
-
An analysis of the exclusion criteria used in observational pharmacoepidemiological studies.
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):329-36
PMID: 16741894
-
Evaluating medication effects outside of clinical trials: new-user designs.
Am J Epidemiol. 2003 Nov 1;158(9):915-20
PMID: 14585769
-
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
J Clin Epidemiol. 2005 Jan;58(1):98-102
PMID: 15649677
-
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
Eur Heart J. 2002 Feb;23(3):207-15
PMID: 11792135
-
Run-in periods in randomized trials: implications for the application of results in clinical practice.
JAMA. 1998 Jan 21;279(3):222-5
PMID: 9438743
-
The exclusion of the elderly and women from clinical trials in acute myocardial infarction.
JAMA. 1992 Sep 16;268(11):1417-22
PMID: 1512909
-
Estimating causal effects from large data sets using propensity scores.
Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63
PMID: 9382394
-
Paradoxical relations of drug treatment with mortality in older persons.
Epidemiology. 2001 Nov;12(6):682-9
PMID: 11679797
-
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.
Am J Cardiol. 1999 Nov 15;84(10):1192-7
PMID: 10569329
-
Long-term persistence in use of statin therapy in elderly patients.
JAMA. 2002 Jul 24-31;288(4):455-61
PMID: 12132975
-
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
Circulation. 1997 Dec 16;96(12):4211-8
PMID: 9416884
-
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies.
Lancet. 2001 Feb 10;357(9254):455-62
PMID: 11273081
-
A review of uses of health care utilization databases for epidemiologic research on therapeutics.
J Clin Epidemiol. 2005 Apr;58(4):323-37
PMID: 15862718
-
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Circulation. 2004 May 4;109(17):2068-73
PMID: 15096449
-
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.
J Clin Epidemiol. 2006 Aug;59(8):819-28
PMID: 16828675
-
Insights into different results from different causal contrasts in the presence of effect-measure modification.
Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):698-709
PMID: 16528796
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Lancet. 2002 Jul 6;360(9326):7-22
PMID: 12114036
-
The treatment of unrelated disorders in patients with chronic medical diseases.
N Engl J Med. 1998 May 21;338(21):1516-20
PMID: 9593791
-
Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus.
J Clin Epidemiol. 1999 Aug;52(8):781-90
PMID: 10465323